BDTX · Company research
Black Diamond Therapeutics, Inc. (BDTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill | BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview ChartMill | View source ↗ | ChartMill | Oct 2, 2026 | neutral | 0 | 0.6 |
| Black Diamond (NASDAQ: BDTX) director takes stock in lieu of cash fees - Stock Titan | Black Diamond (NASDAQ: BDTX) director takes stock in lieu of cash fees Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Black Diamond Therapeutics Inc (BDTX) Stock News Today - TradingKey | Black Diamond Therapeutics Inc (BDTX) Stock News Today TradingKey | View source ↗ | TradingKey | Aug 7, 2026 | neutral | 0 | 0.6 |
| Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha | Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 6, 2026 | neutral | 0 | 0.6 |
| Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth - Simply Wall Street | Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth Simply Wall Street | View source ↗ | Simply Wall Street | Jul 1, 2026 | neutral | 0 | 0.6 |
| BDTX Forecast — Price Target — Prediction for 2027 - TradingView | BDTX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data - Yahoo Finance | BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data Yahoo Finance | View source ↗ | Yahoo Finance | May 25, 2026 | neutral | 0 | 0.6 |
| BDTX Stock Slides As Traders Reprice Downside Volatility - StocksToTrade | BDTX Stock Slides As Traders Reprice Downside Volatility StocksToTrade | View source ↗ | StocksToTrade | May 24, 2026 | neutral | 0 | 0.6 |
| H.C. Wainwright reiterates Black Diamond stock rating on trial data - Investing.com | H.C. Wainwright reiterates Black Diamond stock rating on trial data Investing.com | View source ↗ | Investing.com | May 22, 2026 | neutral | 0 | 0.6 |
| Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response - Stock Titan | Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response Stock Titan | View source ↗ | Stock Titan | May 21, 2026 | neutral | 0 | 0.6 |
| Lung cancer drug trial results to be detailed in Black Diamond webcast - Stock Titan | Lung cancer drug trial results to be detailed in Black Diamond webcast Stock Titan | View source ↗ | Stock Titan | May 19, 2026 | neutral | 0 | 0.6 |
| BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Yahoo Finance | BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right Yahoo Finance | View source ↗ | Yahoo Finance | Apr 23, 2026 | neutral | 0 | 0.6 |
| Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Yahoo Finance | Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Apr 15, 2026 | neutral | 0 | 0.6 |
| Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Price: Oct 2 Close $1.89 - Gotrade | Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Price: Oct 2 Close $1.89 Gotrade | View source ↗ | Gotrade | Jan 13, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Feb 8, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.